Elanco Animal Health (NYSE:ELAN) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Elanco Animal Health (NYSE:ELAN - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01), Zacks reports. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company's quarterly revenue was down 1.4% on a year-over-year basis. During the same period last year, the firm earned $0.08 earnings per share.

Elanco Animal Health Stock Up 2.4 %

Shares of NYSE:ELAN traded up $0.27 during midday trading on Friday, reaching $11.19. The company had a trading volume of 6,902,175 shares, compared to its average volume of 4,960,017. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock's fifty day moving average price is $11.71 and its 200-day moving average price is $13.03. The stock has a market capitalization of $5.53 billion, a P/E ratio of 27.96, a PEG ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a one year low of $10.20 and a one year high of $18.80.

Wall Street Analysts Forecast Growth

ELAN has been the topic of a number of analyst reports. Morgan Stanley dropped their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday. Barclays dropped their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday. UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday. Leerink Partnrs upgraded shares of Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. Finally, Leerink Partners initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a "market perform" rating and a $14.00 price objective on the stock. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $15.83.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.